Despite the failure of an eczema trial in December, Q32 Bio is sticking with bempikibart. But a phase 2-stage complement inhibitor and a number of the biotech’s “valued colleagues” won’t be so lucky.

Ipsen and Sutro Biopharma entered a global licensing deal for STRO-003, an ADC targeting ROR1, overexpressed in cancers, marking Ipsen's first ADC portfolio addition.United States, New York, Jan. 31, ...

The waveLINE-010 trial will compare zilovertamab vedotin, in combination with rituximab plus cyclophosphamide, doxorubicin, ...

A new study shows how an anticancer drug triggers an “outside in” signal that gets it sucked into a cancer cell.

Leveragen has announced a strategic partnership with Moonlight Bio, targeting the development of T-cell therapies for ...

Rituximab, a monoclonal antibody directed against the CD20 molecule found on pre-B cells and mature B cells (but not on plasma cells), was introduced in the late 1990s for the treatment of non ...

Researchers identified that the dominant B cell epitope of Lachnospiraceae flagellins and the utilization of the flagellin ...

Ann LaCasce, MD, MMSc, director of the Dana-Farber/Massachusetts General Brigham Fellowship in Hematology/Oncology, highlights the role of bispecific antibodies in lymphoma research.

Ann LaCasce, MD, MMSc, delved into some of the most recent advances in the lymphoma space, exploring how these new therapies ...

Chronic lymphocytic leukemia (CLL) is a B-cell malignancy, with disease progression ranging from slow and indolent to ...